DUBLIN--(BUSINESS WIRE)--The "Phase I Study Trends and Market Outlook (2020-2024)" report has been added to ResearchAndMarkets.com's offering.
The goal of this report is to provide readers with a high-level view of the Phase I clinical development space to illustrate current market dynamics and inform strategic planning. For this report, 137 Phase I decision-makers were surveyed to share their insights into where the Phase I market is now and what changes they expect over the next four years. Current and predicted study spend and outsourcing proportions are key pieces of information with which sponsors and service providers should be familiar.
Understanding the service provider selection environment is also critical due to the pervasive use of service providers in the Phase I space; respondents have shared key service provider selection criteria for both complex and simple Phase I studies. Finally, staying on top of trends such as the use of challenge trials, diagnostic development, and how companies are responding to the COVID-19 pandemic helps readers stay current with market happenings and plan for what the market is expected to look like in 2024.
What you will learn:
- 4-year examination of the industry's Phase I market dynamics (e.g. study volume, outsourced spend); including the respondent rationale for their predictions
- How outsourced Phase I spend is divided between large CROs, mid-size CROs, dedicated Phase I providers, and AMCs - how this varies by sponsor size and how it is expected to change over time
- The average dollar value of outsourced Phase I studies and the dollar value of studies respondents are comfortable awarding to each provider type
- Which roles have the most responsibility for each of six different decisions related to Phase I study outsourcing
- Evolution of trends in the Phase I market (e.g. diagnostic development, challenge trials, in-silico modeling and simulation, geographic expansion, responses to the COVID-19 pandemic, etc.)
How pharma can use this report:
- Use the predictions of your peers to identify in what types of studies your competition is investing resources and understand how your company's strategy compares to that of the industry
- Ensure your Phase I outsourcing practices are industry-standard or better
How CROs can use this report:
- Utilize this information to ensure your capabilities and capacity are in line with the study types and volume that will be needed in the near future
- Learn which roles are key decision-makers for specific outsourcing-related tasks within sponsor organizations to develop more targeted communications
- Understand the criteria used to select service providers and how the top criteria differ between simple and complex studies
Key Topics Covered:
1. Market Dynamics
- Primary Section Takeaways
- Spend on Phase I Studies
- Outsourced Proportion of Phase I Spend
- Average Value of Outsourced Phase I Study
- Largest Study Comfortable Awarding to Each Provider Type
- Outsourced Spend by Provider Type
2. Provider Perceptions and Selection
- Primary Section Takeaways
- Decision-making Influence by Role
- Preferred Providers
- Number of Preferred Providers
- Desired Provider Characteristics
- Sample Verbatim Responses
- Top Provider Selection Attributes-Simple vs. Complex Studies
3. Trends and Predictions
- Primary Section Takeaways
- Locations of Phase I Studies
- Sponsor Interest in Current Trends
- Pandemic-related Changes in Discussion
4. Study Data
- Study Volume and Design
- Spend on Phase I Studies
- Reasons for Anticipated Increase in Phase I Study Spend
- Reasons for Anticipated Decrease in Phase I Study Spend
- Locations of Phase I Studies
- Phase I Study Subjects
- Development Stage Assets vs. Marketed Products
- In-house Phase I Units
- Locations of Phase I Units
- Outsourcing Practices
- Outsourced Proportion of Phase I Spend
- Reasons for Anticipated Increase in Phase I
- Outsourcing Proportion
- Reasons for Anticipated Decrease in Phase I
- Outsourcing Proportion
- Average Value of Outsourced Phase I Study
- Largest Study Comfortable Awarding to Each Provider Type
- Outsourced Spend by Provider Type
- Benefits of Large, Full-service CROs
- Benefits of Mid-size, Multi-service CROs
- Benefits of Dedicated Phase I Providers
- Benefits of Academic Medical Centers
- Phase I Activity Outsourcing
- Provider Perceptions and Selection
- Number of Preferred Providers
- Proportion of Outsourced Phase I Activities Allocated to Preferred Providers
- Service Provider Familiarity
- Service Provider Use
- Service Provider Preference
- Desired Provider Characteristics
- Top Considered Providers-Complex Studies
- Provider Selection Attributes-Complex Studies
- Top Considered Providers-Simple Studies
- Provider Selection Attributes-Simple Studies
- Reasons Providers Lose Bids
- Decision-making Influence: Designing the Phase I Study
- Decision-making Influence: Deciding whether to Outsource Study
- Decision-making Influence: Holding the Budget for Study Conduct
- Decision-making Influence: Deciding which CROs to Invite to Bid
- Decision-making Influence: Making the Final CRO Selection
- Decision-making Influence: Directly Managing CRO Delivery
- Trends and Predictions
- Recruiting Patient Populations in China
- Recruiting Healthy Volunteers in China
- Study Complexity
- Access to Clinic/Bed Space
- Interest in Challenge Trials
- Interest in Diagnostic Development
- Interest in In-silico Modeling and Simulation
- Change in Study Volume Using Patient Populations
- Change in Study Volume Executed in Multiple Sites/Centers
- Change in Study Volume Executed in Multiple Countries
- Change in Study Volume Executed in Hospitals or Academic Centers
- Involvement in Discussions about Pandemic-related Changes
- Pandemic-related Changes in Discussion
5. Demographics
- Company Size
- Areas of Responsibility
- Drug Development Responsibilities
- Respondent Location
- Job Title
- Recent Outsourcing Involvement
- Drug Development Involvement
- Drug Development Involvement by Phase
For more information about this report visit https://www.researchandmarkets.com/r/szqimi
